We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Elaprase in Children and Adults With Hunter Syndrome (Mucopolysaccharidosis II) in India

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05058391
Recruitment Status : Recruiting
First Posted : September 27, 2021
Last Update Posted : May 6, 2022
Sponsor:
Information provided by (Responsible Party):
Takeda ( Shire )

Brief Summary:

The main aim of this study is to learn more about the safety profile of Elaprase in Indian children and adults with hunter syndrome.

Participants will receive Elaprase once per week over a 3-hour period which can be reduced to 1 hour as determined by the study doctor. Participants will need to visit the clinic weekly during the duration of the study.


Condition or disease Intervention/treatment Phase
Hunter Syndrome Biological: Elaprase Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 5 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective, Multicenter, Single-arm, Open-label, Interventional Phase IV Study to Evaluate the Safety and Efficacy of Idursulfase (r-DNA Origin) (Elaprase™) in Indian Pediatric and Adult Population With Hunter Syndrome (Mucopolysaccharidosis II)
Actual Study Start Date : April 21, 2022
Estimated Primary Completion Date : March 30, 2024
Estimated Study Completion Date : April 30, 2024


Arm Intervention/treatment
Experimental: Elaprase 0.5 mg/kg
Participants will receive a single dose of Elaprase 0.5 milligrams per kilogram (mg/kg) body weight, intravenous infusion on Day 1, Week 1 followed by every week up to end of treatment (EOT) (Day 358, Week 52).
Biological: Elaprase
Participants will receive a single dose of Elaprase 0.5 mg/kg intravenous infusion every week on Day 1.
Other Name: Idursulfase




Primary Outcome Measures :
  1. Number of Participants With Adverse Events (AEs) [ Time Frame: From start of the study drug administration up to end of study (EOS) (Week 53) ]
    An adverse event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (example, a clinically significant abnormal laboratory value), symptom, or disease temporally associated with the use of a drug whether or not it is considered related to the drug. A serious adverse event (SAE) is defined as any untoward medical occurrence that at any dose results in: death; is life-threatening: requires inpatient hospitalization or results in prolongation of existing hospitalization; persistent or significant disability/incapacity; leads to a congenital anomaly/birth defect or is an important medical event. AEs include SAEs, treatment emergent AEs, treatment emergent SAEs, discontinuation due to AEs, and death.

  2. Number of Participants With Adverse Drug Reactions (ADRs) [ Time Frame: From start of the study drug administration up to EOS (Week 53) ]
    An ADR is defined as a response to a drug which is noxious and unintended, and which occurs at doses normally used in humans for prophylaxis, diagnosis, or therapy of disease, or for the modification of physiological function.

  3. Number of Participants With Infusion-related Reactions (IRRs)) [ Time Frame: From start of the study drug administration up to EOS (Week 53) ]
    An IRR is defined as an AE that has been assessed as at least possibly related to treatment with Elaprase and occurs during an infusion or up to 24 hours post-infusion.


Secondary Outcome Measures :
  1. Change From Baseline in Percentage Forced Vital Capacity (%FVC) at Week 27 and 53 [ Time Frame: Baseline, Weeks 27 and 53 ]
    FVC is the amount of air that can be forcibly exhaled from your lungs after taking the deepest breath possible, as measured by spirometry. FVC is a measure of respiratory function.

  2. Change From Baseline in 6 Minute Walk Test (6MWT) at Week 27 and 53 [ Time Frame: Baseline, Weeks 27 and 53 ]
    6MWT is a measure of physical functional capacity which is determined on a walking course.

  3. Change From Baseline in Cardiac Left Ventricular Mass Index (LVMI) at Week 27 and 53 [ Time Frame: Baseline, Weeks 27 and 53 ]
    Cardiac LVMI will be measured by 2-dimensional (2D) echocardiography. Cardiac LVMI is the left ventricular mass (LVM, in grams [g]) indexed to body surface area (BSA), in square meter (m^2). Cardiac LVMI (in gram per square meter [g/m^2])=LVM divided by BSA.

  4. Change From Baseline in Ejection Fraction at Week 27 and 53 [ Time Frame: Baseline, Weeks 27 and 53 ]
    The Ejection Fraction is measured by 2D echocardiography and considered a sufficiently sensitive measure to evaluate any changes in cardiac function.

  5. Change From Baseline in Liver Volume at Week 27 and 53 [ Time Frame: Baseline, Weeks 27 and 53 ]
    Liver volume will be determined by Ultrasonography (USG). Hepatomegaly is defined as a liver volume (Liter [L]) greater than (>) 3.5% of body weight (kilogram [kg]) in participants aged 5-12 years, 2.2% of body weight in participants aged 13-17 years, and >2.6% in participants more than 18 years old (30).

  6. Change From Baseline in Spleen Volume at Week 27 and 53 [ Time Frame: Baseline, Weeks 27 and 53 ]
    Spleen volume will be determined by USG. Splenomegaly is defined as having a splenic volume greater than the 95th percentile of the normal distribution in children.

  7. Change From Baseline in Normalized Urine Glycosaminoglycan (uGAG) Levels at Week 14, 27, 40, and 53 [ Time Frame: Baseline, Weeks 14, 27, 40, and 53 ]
    Normalized uGAG will be analyzed using urine testing. The uGAG levels will be normalized to urine creatinine and will be reported as microgram GAG per milligram creatinine (mcg GAG/mg creatinine).

  8. Change From Baseline in Global Joint Range of Motion (JROM) Score at Week 27 and 53 [ Time Frame: Baseline, Weeks 27 and 53 ]
    Passive joint mobility is defined as the range of motion of the shoulder, elbow, wrist, hip, knee, and ankle joints, as assessed by one expert physician using universal goniometry method. Global JROM (% of normal range of motion) is the average of 11 ratios multiplied by 100. Ratios are left/right means of passive range of motion in shoulder (flexion/extension, abduction, internal/external rotation), elbow (flexion/extension), wrist (flexion/extension), index finger (flexion/extension [combined metacarpophalangeal joint, proximal interphalangeal joint, distal interphalangeal joint motion]), hip (flexion/extension, abduction, internal/external rotation), knee (flexion/extension), and ankle (dorsiflexion) divided by the normal range (American Academy of Orthopedic Surgeons and American Medical Association). It ranges from 0-100 where, 0- No movement and 100- Normal.

  9. Change From Baseline in Anthropometric Parameter (Height) [ Time Frame: Baseline, Weeks 27 and 53 ]
    Change from baseline in height (centimeters) will be assessed in participants less than (<) 18 years at Weeks 27 and 53.

  10. Change From Baseline in Anthropometric Parameter (Weight) at Weeks 27 and 53 [ Time Frame: Baseline, Weeks 27 and 53 ]
    Change from baseline in weight (kilograms) will be assessed in all participants at Weeks 27 and 53.

  11. Change From Baseline in the Health-related Quality of Life (HRQoL) Based on Hunter Syndrome-Functional Outcomes for Clinical Understanding Scale (HS-FOCUS) [ Time Frame: Baseline, Weeks 27 and 53 ]
    HS-FOCUS was developed as disease-specific measure of the impact of Hunter syndrome on HRQL. The HS-FOCUS is designed to gather information on the participant's daily life and wellbeing, satisfaction with treatment, and hospitalizations, as well as on how Hunter syndrome impacts participant's general quality of life. HS-FOCUS includes 2 validated components: a parent version and a participant self-reported version for those over age 12 years. The HS-FOCUS (shortened version) questionnaire has 5 function domains (walking/standing, grip/reach, school/work, activities, and breathing). Items are scored using a response scale from 0 to 3, with 0 signifying an ability to complete the activity-related functions 'without any difficulty' and 3 score denoting highest disability.

  12. Change From Baseline in the HRQoL Based on Childhood Health Assessment Questionnaire (CHAQ) [ Time Frame: Baseline, Weeks 27 and 53 ]
    The CHAQ was initially developed for assessing juvenile idiopathic arthritis, from the perspective of the parent or participant, and has been previously applied to other chronic disabling conditions such as Hunter syndrome. It is a 30-item instrument that measures functional capacity and independence in activities of daily life across eight domains: dressing and grooming, arising, eating, walking, reach, grip, hygiene, and activities. For each domain, there is a 4-level difficulty scale that is scored from 0 to 3, with 0 corresponding to 'without any difficulty' and 3 to 'unable to do'.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female Elaprase naive participants (and who are not part of any other program at the time of study enrollment and during the study period) of any age with confirmed diagnosis of Hunter syndrome based on the following documented biochemical and genetic criteria:

    • Documented deficiency in iduronate 2-sulfatase (IDS [12S]) enzyme activity of less than or equal to 10 percent (%) of the lower limit of the normal range as measured in plasma, fibroblasts, or leukocytes (based on normal range of measuring laboratory).
    • A normal enzyme activity level of one other sulfatase as measured in plasma, fibroblasts, or leukocytes (based on normal range of measuring laboratory).
    • The participant has a documented mutation in the IDS gene.
  • In the opinion of the investigator, the participant or the participant's parents/guardians are capable of understanding and complying with protocol requirements.
  • The participant or, when applicable, the participant's parents/guardians/legal authorized representative (LAR) signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures. If the participant participating in this study is greater than or equal to (>=) 7 years and less than (<) 18 years of age signs and dates an assent form.
  • A male participant who is nonsterilized and sexually active with a female partner of childbearing potential agrees to use barrier method of contraception (example, condom with or without spermicide) from signing of informed consent throughout the duration of the study. The female partner of a male participant should also be advised to use a highly effective/effective method of contraception.
  • A female participant of childbearing potential who is sexually active with a nonsterilized male partner agrees to use a highly effective method of contraception from signing of informed consent throughout the duration of the study.

Exclusion criteria:

  • Participant has received hematopoietic stem cell transplant (HSCT) or a bone marrow transplant at any time.
  • Participant is unable to comply with the protocol, example, uncooperative with protocol schedule, refusal to agree to all of the study procedures, inability to return for safety evaluations, or is otherwise unlikely to complete the study, as determined by the investigator.
  • Participant is suffering from any comorbid conditions (including hepatic impairment, acute or chronic) or having any other clinical observation or history during the screening examination, which would interfere with the objectives of the study as per investigators judgement.
  • The participant has a chronic kidney disease with estimated Glomerular Filtration rate less than 15 milliliter per minute per 1.73 meter square (mL/min/1.73 m^2) and/or is on dialysis.
  • The participant is an immediate family member, study site employee, or is in a dependent relationship with a study site employee who is involved in conduct of this study (example, spouse, parent, child, sibling) or may consent under duress.
  • The participant has a history of hypersensitivity or allergies to related compounds including any associated excipients.
  • If female, the participant is pregnant or lactating or intending to become pregnant before participating in this study, during the study; or intending to donate ova during such time period.
  • If male, the participant intends to donate sperm during the course of this study.
  • The participant has participated in another clinical study or received any investigational compound or non-investigational idursulfase beta within the past 30 days before informed consent.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05058391


Contacts
Layout table for location contacts
Contact: Shire Contact +1 866 842 5335 ClinicalTransparency@takeda.com

Locations
Layout table for location information
India
SAT Hospital - Govt Medical College Not yet recruiting
Thiruvananthapuram, Kerala, India, 69501
Contact: Site Contact    +91-9349930828    sankarvh@gmail.com   
Principal Investigator: Dr. Sankar VH, MBBS, MD, DCH, MNAMS, DM         
JK Lone Hospital Not yet recruiting
Jaipur, Rajasthan, India, 302004
Contact: Site Contact    +91-9982451490    priyanshu82@gmail.com   
Principal Investigator: Dr. Priyanshu Mathur, MBBS, MD, Fellowship Metabolic         
Institute of Child Health Recruiting
Kolkata, India, 700017
Contact: Site Contact    +91-9831075734    monjorimr@gmail.com   
Principal Investigator: Dr. Monjori Mitra, MBBS, DCH, DNB         
All India Institute of Medical Sciences (AIIMS) Not yet recruiting
New Delhi, India, 110 029
Contact: Site Contact    91-11-26588663    neerja17aiims@gmail.com   
Principal Investigator: Dr. Neerja Gupta, MBBS, MD, DM         
Sir Gangaram Hospital Not yet recruiting
New Delhi, India, 110060
Contact: Site Contact    +91-11-25861767    ratnadpuri@yahoo.com   
Principal Investigator: Dr. Ratna Dua Puri, MBBS, DM, MD         
Sponsors and Collaborators
Shire
Investigators
Layout table for investigator information
Study Director: Study Director Takeda
Additional Information:
Layout table for additonal information
Responsible Party: Shire
ClinicalTrials.gov Identifier: NCT05058391    
Other Study ID Numbers: TAK-665-4001
First Posted: September 27, 2021    Key Record Dates
Last Update Posted: May 6, 2022
Last Verified: May 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Clinical Study Report (CSR)
Access Criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/ For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
URL: https://vivli.org/ourmember/takeda/

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Takeda ( Shire ):
Mucopolysaccharidosis II
Additional relevant MeSH terms:
Layout table for MeSH terms
Mucopolysaccharidosis II
Mucopolysaccharidoses
Syndrome
Disease
Pathologic Processes
Carbohydrate Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Lysosomal Storage Diseases
Mucinoses
Connective Tissue Diseases
Metabolic Diseases
Mental Retardation, X-Linked
Intellectual Disability
Neurobehavioral Manifestations
Neurologic Manifestations
Nervous System Diseases
Genetic Diseases, X-Linked
Heredodegenerative Disorders, Nervous System